As much as we try to avoid it, we are constantly sharing germs with those around us. But even when two people have the same infection, the resulting illnesses can be dramatically different—mild for one person, severe or even life-threatening for the other.
Now, new research from The Rockefeller University offers insights into how these differences arise. Jean-Laurent Casanova, head of St. Giles Laboratory of Human Genetics of Infectious Diseases and Howard Hughes Medical Institute Investigator, led a team of researchers to uncover how two different conditions—a genetic immunodeficiency and delayed acquired immunity—can combine to produce a life-threatening infection.
Genetic mutation impairs immunity
In the research, published online on February 23 in Cell, Casanova and his team focused on the case of an otherwise healthy young girl who developed a life-threatening infection from a very common strain of bacterium. Most of us carry this microbe, known as Staphylococcus aureus, on our skin and in our nostrils. It can cause minor infections (often referred to as “staph infections”), but in some people, it results in severe disease.
The young girl’s illness was mysterious: she had no known risk factors that would lead her to develop the acute form of the disease, and none of her family members had contracted it. So Casanova and his team set out to define the underlying cause of her disease by searching her DNA for mutations that might make her more susceptible to staph disease.
They quickly identified a likely culprit—a single letter substitution in the two copies of a gene that encodes for a protein known as TIRAP, used by specific immune cells to flag invading bacteria.
In laboratory experiments, the researchers found that TIRAP is critical for cells in the immune system’s first line of defense against invaders. These are cells that develop before we are born, with built-in recognition systems for a host of molecules that are frequently present on the surface of invaders.
“We were sure this was the explanation for the severity of her staphylococcal disease,” says Casanova. “We thought we had it all figured out.”
But things turned out to be more complicated. To test his hypothesis, Casanova decided to analyze the DNA of other members of the patient’s family. They hadn’t suffered from severe staph infections, so they should have had normal TIRAP genes. However, he found the opposite—all seven members of her family had the same mutation as the young patient.
The researchers now had two questions instead of just one: Why did this child get the invasive disease? And why were the rest of her family seemingly immune, even though they shared her immune-compromising mutation?
The answers lie in a second line of immune defense that is not encoded within our DNA at birth. These secondary defenses are dependent on cells that generate antibodies against foreign compounds. “This is not something we are born with, but instead it is resistance that we acquire over the course of our lifetime when we are exposed to new pathogens,” Casanova explains.
The researchers found that the patient lacked antibodies against a single molecule, known as LTA, but the levels were normal for all of her family members. LTA is present on the surface of staphylococcal bacteria, and normally it is recognized by immune cells in both lines of defense.
The antibodies against LTA were able to restore the function of the patient’s immune cells in culture systems, and the researchers went on to confirm their hypothesis using a mouse model of the disease.
The results explain both why the patient developed life-threatening disease and why her family members didn’t. “Her illness likely resulted from failures in both lines of immunity. In her family, the second layer of defense compensated for genetic defects in the first,” explains Casanova. “More broadly, it offers insight into how two people with the same infection, and even the same DNA, can have very different illnesses.”
This work was supported by INSERM, Paris Descartes University, the Imagine Institute (ANR-10-LABX-62-IBEID, ANR-2012-BSV3-0003-02, ANR-10-IAHU-01), the St. Giles Foundation, the National Center for Research Resources, the National Center for Advancing Sciences of the NIH (8UL1TR000043), the Innovative Medicines Initiative Joint Undertaking (115523), COMBACTE, from the European Union’s FP7/2007-2013, EFPIA, Fondation pour la Recherche Médicale, the Thrasher Research Fund, and the AXA Research Fund.
|Cell, online: February 23, 2017
Human Adaptive Immunity Rescues an Inborn Error of Innate Immunity
Laura Israel, Ying Wang, Katarzyna Bulek, Erika Della Mina, Zhao Zhang, Vincent Pedergnagna, Maya Chrabieh, Nicole A. Lemmens, Vanessa Sancho-Shimizu, Marc Descatoire, Théo Lasseau, Elisabeth Israelsson, Lazaro Lorenzo, Ling Yun, Aziz Belkadi, Andrew Moran, Leonard E. Weisman, François Vandenesh, Frederic Batteux, Sandra Weller, Michael Levin, Jethro Herberg, Avinash Abhyankar, Carolina Prando, Yuval Itan, Willem van Wamel, Capucine Picard, Laurent Abel, Damien Chaussabel, Xiaoxia Li, Bruce Beutler, Peter D. Arkwright, Jean-Laurent Casanova and Anne Puel